Article

A Randomized, Double-Blind, Placebo-Controlled, Trial of Lamotrigine Therapy in Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence

Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology (Impact Factor: 7.05). 06/2012; 37(11):2347-54. DOI: 10.1038/npp.2012.90
Source: PubMed

ABSTRACT

Bipolar disorder is associated with very high rates of substance dependence. Cocaine use is particularly common. However, limited data are available on the treatment of this population. A 10-week, randomized, double-blind, placebo-controlled trial of lamotrigine was conducted in 120 outpatients with bipolar disorder, depressed or mixed mood state, and cocaine dependence. Other substance use was not exclusionary. Cocaine use was quantified weekly by urine drug screens and participant report using the timeline follow-back method. Mood was assessed with the Hamilton rating scale for depression, quick inventory of depressive symptomatology self-report, and young mania rating scale. Cocaine craving was assessed with the cocaine-craving questionnaire. Data were analyzed using a random regression analysis that used all available data from participants with at least one postbaseline assessment (n=112). Lamotrigine and placebo groups were similar demographically (age 45.1±7.3 vs 43.5±10.0 years, 41.8% vs 38.6% women). Urine drug screens (primary outcome measure) and mood symptoms were not significantly different between groups. However, dollars spent on cocaine showed a significant initial (baseline to week 1, p=0.01) and by-week (weeks 1-10, p=0.05) decrease in dollars spent on cocaine, favoring lamotrigine. Few positive trials of medications for cocaine use, other than stimulant replacement, have been reported, and none have been reported for bipolar disorder. Reduction in amount of cocaine use by self-report with lamotrigine suggests that a standard treatment for bipolar disorder may reduce cocaine use. A study limitation was weekly assessment of urine drug screens that decreased the ability to detect between-group differences.

Download full-text

Full-text

Available from: E. Sherwood Brown, Jun 03, 2014
  • Source
    • "Subsequently, several case report [39] and small-scaled open trials [40] [41] all favored lamotrigine to reduce cocaine craving. A recent large-scaled (N = 112), randomized, double-blind, placebo-controlled trial in patients who had bipolar disorder, either in depressed or mixed phase, comorbid with cocaine use disorder, the results showed lamotrigine significantly decreased the money spent on cocaine, though the urine drug screening (primary outcome measurement) and mood symptoms were not significantly different between groups [42]. An open-labeled study using add-on design in 28 outpatients with bipolar disorder and alcohol use disorder [43] showed not only significant improvement in Hamilton Rating Scale for Depression , Young Mania Rating Scale, and Brief Psychiatric Rating Scale scores (P < 0.01), but also a reduction in craving and carbohydrate-deficient transferrin levels (P < 0.001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ketamine is an anesthetic derivative of phencyclidine (PCP; 'Angel dust') with dissociative, analgesic and psychedelic properties. Ketamine has become a popular recreational drug of abuse in many parts of the world in recent years. The preclinical studies demonstrate the reinforcing effects of ketamine and long-term ketamine abuse induces a delayed and persistent upregulation of dopamine system. In humans, there have been concerns about its liability to development of addiction. The dilemma of mental professionals in managing the treatment-seeking ketamine abusers comes from a lack of effective pharmacotherapy. Limiting evidence showed that lamotrigine, which inhibits glutamate release, is effective to reduce cocaine craving. We propose that lamotrigine might be beneficial for managing ketamine use disorder clinically. We also reported one case of ketamine use disorder who experienced a great reduction in craving and ketamine use after taking lamotrigine. Although the mechanisms underlying neuroadaptation and reward related to ketamine are not entirely clear, future clinical trials are needed to advance our understanding of the benefit yielded by lamotrigine to treat ketamine use disorder.
    Full-text · Article · Nov 2015 · Medical Hypotheses
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Methamphetamine use disorders are common and severe problems. Persons with mood disorders, particularly bipolar disorder, have high rates of substance use disorders. We previously reported promising findings on drug use, memory and study retention in patients with a history of mania and cocaine dependence given the nutritional supplement citicoline. In the current proof-of-concept study, we examined citicoline in bipolar or unipolar depression and methamphetamine dependence. METHODS: Sixty adults with bipolar depression or major depressive disorder and methamphetamine dependence were randomized to citicoline (2000mg/day) or placebo for 12 weeks. Mood was assessed using Inventory of Depressive Symptomatology-Clinician Version (IDS-C), and cognition with the Hopkins Auditory Verbal Learning Test (HVLT). Drug use was assessed by urine drug screens. RESULTS: An ANCOVA of the intent-to-treat sample showed that those receiving citicoline (n=28) had a statistically significantly greater improvement in IDS-C scores than those receiving placebo (n=20). Survival in the study was significantly longer and completion rates significantly greater with citicoline than placebo. No significant differences were observed in memory or methamphetamine use. Citicoline was well tolerated. LIMITATIONS: Sample heterogeneity and small sample size were limitations. CONCLUSIONS: To our knowledge this is the first placebo-controlled trial in a dual diagnosis sample with methamphetamine use disorders. Findings suggest that citicoline may have antidepressant properties in this population. Greater treatment retention with citicoline is also noteworthy in a patient population with substance dependence. Larger trials targeting depressive symptoms and treatment retention seem warranted.
    No preview · Article · Sep 2012 · Journal of Affective Disorders
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bipolar disorder is a chronic, disabling, frequent and highly comorbid illness. It is often associated with addictive disorders (ADDs), another chronic and relapsing condition, with a lifetime prevalence three to five times higher than in the general population. However, knowledge is scarce about the possible mechanisms and the optimal treatment of this co-occurrence. Moreover, previous research has focused on separate ADDs, and few incidence data were available at the time. Our objective was, therefore, to evaluate the relevance of regrouping ADDs as classified in the preliminary version of the DSM-V in understanding the comorbidity of bipolar and ADDs. Using a comprehensive review of the existing literature, we report similar correlates across ADDs when comorbid with bipolar disorder and the theoretical implications of these findings are discussed. We also identified specific targets for new research in this field, which is urgent given the frequency of this comorbidity.
    No preview · Article · Dec 2012
Show more

Similar Publications